For the Inventor, By the Inventor

Enter assignee name

Chicago, IL, United States of America

Exicure, Inc.

USPTO Granted Patents = 9

% Expired Patents = 22.2

EPO Patents = 2

Trademarks = 2

Forward Citations = 74

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Sergei M Gryaznov (8 out of 84 patents)

Christopher C Mader (8 out of 10 patents)

Aleksandar Filip Radovic-Moreno (6 out of 23 patents)

4. Chad A Mirkin (3 out of 168 patents)

5. SonBinh T Nguyen (3 out of 30 patents)

6. Richard Kang (3 out of 7 patents)

7. Subbarao Nallagatla (3 out of 6 patents)

8. Resham Singh Banga (3 out of 3 patents)

9. Natalia Chernyak (3 out of 3 patents)

10. Weston Daniel (3 out of 7 patents)

11. Aaron Love (2 out of 2 patents)

12. Warefta Hasan (2 out of 2 patents)

13. Tiffany L Halo (2 out of 2 patents)

14. Scott Mix (1 out of 2 patents)

9 patents: Sort by Forward Citations

1. 11883535 - Liposomal particles, methods of making same and uses thereof (2024-01-30),

2. 10894963 - Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use (2021-01-19),

3. 10837018 - Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use (2020-11-17),

4. 10792251 - Liposomal particles, methods of making same and uses thereof (2020-10-06),

5. 10760080 - Anti-TNF compounds (2020-09-01),

6. 10704043 - Nucleic acid nanostructures with core motifs (2020-07-07),

7. 10434064 - Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications (2019-10-08),

8. 10208310 - Anti-TNF compounds (2019-02-19),

9. 10182988 - Liposomal particles, methods of making same and uses thereof (2019-01-22),

Exicure, Inc. is a clinical-stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs based on their proprietary spherical nucleic acid (SNA) technology. Their pipeline is focused on targeting diseases such as cancer, inflammatory disorders, and genetic diseases. Exicure's lead product candidate, AST-008, is currently in clinical trials for the treatment of advanced solid tumors.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

9 Patents

#384 in Chicago, IL

#1,548 in Illinois

#32,526 in US

Chicago, IL, United States of America

Exicure, Inc.

Forward Citations = 74

14 inventors:

Sergei M Gryaznov (8 out of 84 patents)

Christopher C Mader (8 out of 10 patents)

Aleksandar Filip Radovic-Moreno (6 out of 23 patents)

4. Chad A Mirkin (3 out of 168 patents)

5. SonBinh T Nguyen (3 out of 30 patents)

Please report any incorrect information to [email protected]

Loading…